EMD Serono‘s atacicept can effectively reduce disease activity among lupus patients with high disease activity at baseline, according to new data from the Phase 2b ADDRESS II trial. The study, “Attainment of Low Disease Activity By Patients with Systemic Lupus Erythematosus Starting with High Disease Activity in a 24-Week,…

Janssen announced that its investigational antibody Stelara (ustekinumab) showed positive results in a Phase 2 trial as a therapy for patients with systemic lupus erythematosus (SLE). Based on these results, the company said it would further test Stelara in a Phase 3 development program planned for 2018. The study, “Efficacy and…

Bilingual groups providing support and education to systemic lupus erythematosus (SLE) patients and their family members  — people who live in minority U.S. neighborhoods — considerably help them to manage and cope with the disease, a survey shows. The findings were recently presented at the recent American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) annual…

A person’s race and socioeconomic status in the U.S. can lead to delays both in diagnosing systemic lupus erythematosus (SLE) and the start of specialty care, according to findings presented at the recent American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting in Washington, D.C. Researchers from the California…

Merck recently reported positive results from its Phase 2b study of the experimental drug atacicept as a treatment for systemic lupus erythematosus, with particularly good results in patients with high disease activity. The study, “Efficacy and Safety of Atacicept in Patients with Systemic Lupus Erythematosus: Results of a 24-week Randomized,…

Aurinia Pharmaceuticals announced that it will present positive data from its Phase 2b clinical trial evaluating the efficacy and safety of voclosporin for the treatment of lupus nephritis, showing that the study had met and confirmed its primary endpoint of complete remission in a statistically significant number of treated patients. The data…

Mallinckrodt Pharmaceuticals has revealed that H.P. Acthar Gel is effective in the treatment of patients with persistently active systemic lupus erythematosus (SLE) who are under corticosteroid therapy, according to recent study results. Though the study’s primary endpoint was not met, the drug led to attenuation of disease activity in participants and met some…